Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: A nationwide multicenter cooperative study

Journal of Gastroenterology

Volumn 48, Issue 3, 2013, Pages 382-390

  Izumi, Namiki ^a   Asahina, Yasuhiro ^a   Kurosaki, Masayuki ^a   Yamada, Gotaro ^b   Kawai, Tsutomu ^c   Kajiwara, Eiji ^d   Okamura, Yukishige ^e   Takeuchi, Takayuki ^f   Yokosuka, Osamu ^g   Kariyama, Kazuya ^h   Toyoda, Joji ⁱ   Inao, Mie ^j   Tanaka, Eiji ^k   Moriwaki, Hisataka ^l   Adachi, Hiroshi ^m   Katsushima, Shinji ⁿ   Kudo, Masatoshi ^o   Takaguchi, Kouichi ^p   Hiasa, Yoichi ^q   Chayama, Kazuaki ^r   Yatsuhashi, Hiroshi ^s   Oketani, Makoto ^t   Kumada, Hiromitsu ^u   more..

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c Kanbara General Hospital   (Japan)

^d Department of Gastroenterology   (Japan)

^e Department of Gastroenterology   (Japan)

^f Notogawa Hospital   (Japan)

^g CHIBA UNIVERSITY   (Japan)

^h Okayama Citizens Hospital   (Japan)

ⁱ Sapporo Kousei Hospital   (Japan)

^j SAITAMA MEDICAL UNIVERSITY   (Japan)

^k SHINSHU UNIVERSITY   (Japan)

^l GIFU UNIVERSITY   (Japan)

^m TONAMI GENERAL HOSPITAL   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^o KINKI UNIVERSITY   (Japan)

^p KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^q EHIME UNIVERSITY   (Japan)

^r HIROSHIMA UNIVERSITY   (Japan)

^s NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^t KAGOSHIMA UNIVERSITY   (Japan)

^u TORANOMON HOSPITAL   (Japan)

more..

Author keywords

Chronic hepatitis C; Hepatocellular carcinoma; Peginterferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; BILIRUBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; COOPERATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPAN; LIVER CELL CARCINOMA; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SEX RATIO; THROMBOCYTE COUNT; DRUG ADMINISTRATION; INCIDENCE; LIVER TUMOR; MULTICENTER STUDY; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84884621797     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0641-9     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. doi:10.3322/canjclin. 55.2.74.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17. doi:10.1016/S0140-6736(03)14964-1.
3. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano K, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671-5. doi:10.1002/hep.1840120409.
4. Namiki I, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh T, et al. Management of hepatitis C; Report of the consensus meeting at the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:347-68. doi:10.1111/j. 1872-034X.2010.00642.x.
5. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shin JW, Gojobori T, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA. 2002;99:11584-9. doi: 10.1073/pnas.242608099.
6. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinoma in patients with chronic hepatitis type C: a long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29: 1124-30.
7. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 1998;129: 94-9.
8. Bruno S, Stroffolini T, Colombo M, Bollani S, Benveguu L, Mazzella G, et al. Sustained virological response to interferonalpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579-87. doi: 10.1002/hep.21492.
9. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147: 677-84.
10. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52:518-27. doi:10.1002/hep.23691.
11. Amarapurkar D, Han KH, Chan HL, Ueno Y, Asia-Pacific working party on prevention of hepatocellular carcinoma. Application of surveillance programs for hepatocellular carcinoma in the Asia- Pacific Region. J Gastroenterol Hepatol. 2009;24:955-61. doi: 10.1111/j.1440-1746.2009.05805.x.
12. Tamura Y, Yamagiwa S, Aoki Y, Kurita S, Suda T, Ohkoshi S, et al. Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci. 2009;54: 2530-7.
13. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359:2429-41. doi:10.1056/NEJMoa0707615.
14. Lok AS, Everhart JE, Wright EC, Di Bischeglie AM, Kim HY, Stering RK, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011;140:840-9. doi: 10.1053/j.gastro.2010.11.050.
15. Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, et al.Maintenance therapywith peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011;140:1990-9. doi:10.1053/j.gastro.2010.11.050.
16. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, et al. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol. 2007;79:1095-102. doi:10.1002/jmv.20866.
17. Poynard T, Moussali J, Ratziu V, Regimberu C, Opolan P. Effects of interferon therapy in "non-responder" patients with chronic hepatitis C. J Hepatol. 1999;31S:178-83. doi:10.1016/S0168-8278(99)80397-3.
18. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer P. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513-20. doi:10.1016/0270-9139(94)90 250-X, doi:10.1002/hep.1840190629.
19. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140:1182-8. doi:10.1053/j.gastro.2010. 12.032.
20. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature. 2009;461:399-401. doi:10.1038/nature08309.
21. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature. 2009;41: 1105-9.
22. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, et al. IL-28B rs 12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development ofHCC. JHepatol. 2011;54:716-22. doi:10.1016/j.jhep. 2010.07.019.
23. Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, et al. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol Res. 2010;40:870-7. doi:10.1111/j. 1872-034X.2010.00692.x.
24. Koike K. Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. J Gastroenterol. 2009;44(Suppl 19):82-8. doi:10.1007/s00535- 008-2276-4.
25. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofman WP, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology. 2008;47:1856-62. doi:10.1002/hep.22251.
26. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006;43:1295-302. doi: 10.1002/hep.21208.
27. Furutani T, Hino K, Okuda M, Gondo T, Nishina S, Kitase A, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology. 2006;130:2087-98. doi:10.1053/j.gastro.2006. 02.060.
28. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002;89:418-22. doi: 10.1046/j.0007-1323.2001.02054.x.
29. Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology. 2007;72(Suppl 1):132-8. doi: 10.1159/000111719.
30. Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851-8. doi:10.1111/j.1365-2036.2010.04414.x.
31. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat. 2010;17:287-92. doi:10.1111/j.1365-2893.2009.01181.x.
32. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, et al. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol. 2007;79:1485-90. doi:10.1002/jmv.20925.
33. Nomura H, Kashiwagi Y, Hirano R, Tanimoto H, Tsutsumi N, Higashi M, et al. Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: a pilot study. Hepatol Res. 2007;37:490-7. doi:10.1111/j.1872-034X.2007.00073.x.
34. Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, et al. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007;22:669-75. doi: 10.1111/j.1440-1746.2007.04898.x.
35. Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, et al. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. J Gastroenterol. 2012;47: 444-51.